The Massachusetts biotech will focus its efforts and resources into cemsidomide, an oral drug candidate being trialed for multiple myeloma and non-Hodgkin lymphoma.

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

MassBio’s new report outlines several concerns, including NIH cuts undermining the research engine, FDA reductions delaying ...

Imports of pharmaceutical products surged in March, most of which came from Ireland, historically one of the biggest ...

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing ...

The oncologist and former University of California, San Francisco, professor has long been critical of COVID-19 mandates and ...

A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while ...

Twenty attorneys general allege that the recent workforce reduction at the Department of Health and Human Services is ...